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Abstract
Background: translation of the available evidence concerning primary cardiovascular prevention into clinical guidance for the
heterogeneous population of older adults is challenging. With this review, we aimed to give an overview of the thresholds and
targets of antihypertensive drug therapy for older adults in currently used guidelines on primary cardiovascular prevention.
Secondly, we evaluated the relationship between the advised targets and guideline characteristics, including guideline quality.
Methods: we systematically searched PubMed, Embase, Emcare and five guideline databases. We selected guidelines with
(i) numerical thresholds for the initiation or target values of antihypertensive drug therapy in context of primary prevention
(January 2008–July 2020) and (ii) specific advice concerning antihypertensive drug therapy in older adults. We extracted the
recommendations and appraised the quality of included guidelines with the AGREE II instrument.
Results: thirty-four guidelines provided recommendations concerning antihypertensive drug therapy in older adults. Twenty
advised a higher target of systolic blood pressure (SBP) for octogenarians in comparison with the general population and
three advised a lower target. Over half of the guidelines (n = 18) recommended to target a SBP <150 mmHg in the oldest
old, while four endorsed targets of SBP lower than 130 or 120 mmHg. Although many guidelines acknowledged frailty, only
three gave specific thresholds and targets. Guideline characteristics, including methodological quality, were not related with
the recommended targets.
Conclusion: the ongoing debate concerning targets of antihypertensive treatment in older adults, is reflected in an
inconsistency of recommendations across guidelines. Recommended targets are largely set on chronological rather than
biological age.
Keywords: older people, primary cardiovascular prevention, guidelines, antihypertensive drug therapy, systematic review
Key points
• The debate concerning blood pressure targets in older adults is reflected in an inconsistency of guideline recommendations.
• Notably for the oldest old and especially across the most rigorously developed guidelines.
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Background
Hypertension is the worldwide leading predisposing condi-
tion for disease burden, and as the most important modifi-
able risk factor, its management forms an essential pillar of
primary prevention of cardiovascular diseases [1, 2]. Glob-
ally, hypertension is prevalent in roughly one in four adults
and steadily rises with age [3, 4]. For example, data from
the Framingham Heart Study showed that more than 90%
of the normotensive participants between 55 and 65 years
developed hypertension [5], emphasizing the need for a
thoughtful treatment strategy. Nevertheless, an international
analysis of health surveys estimated that the proportion
of hypertensive adults between 35 and 85 years receiv-
ing antihypertensive drug therapy ranges from 29.0% to
80.5% [6].
Only during the last three decades randomized clinical
trials (RCTs) have demonstrated that pharmacological treat-
ment of hypertension in older adults is beneficial [7–9].
Although those studies included octogenarians, frail older
adults are largely underrepresented as many of them are
excluded from trials due to their comorbidities [10–12]. To
date, no interventional studies specific to antihypertensive
treatment in older frail individuals have been conducted.
Several population-based cohort studies [13, 14], in contrast,
have shown that low blood pressure (BP) under antihy-
pertensive drug treatment, especially in older adults with
frailty or other complex health problems [15], is associ-
ated with higher all-cause mortality rates. Despite the high
quality of the available evidence, translation into clinical
guidance for the heterogeneous population of older adults is
challenging.
In the current discussion on hypertension management
in older adults, the clinical problem is not only when to
start, but predominantly how low the target BP needs to
be [12, 16, 17]. This intensity and thereby numerical tar-
get of antihypertensive drug therapy is set on the balance
between cardiovascular risk reduction and chance of side
effects. Recent trial evidence favours intensive treatment for
most patients [18, 19]; however, frail older adults seem to
be at higher risk for both cardiovascular events and severe
side effects of antihypertensive drug therapy, resulting in an
unclear net benefit [20, 21].
Because translation of the available evidence concerning
primary cardiovascular prevention into clinical guidance for
older adults is challenging, insight into the actual guide-
lines about hypertension management will contribute to the
present debate. Therefore, the primary aim of this review was
to provide a systematic, cross-continental and present-day
overview of the thresholds and targets of antihypertensive
drug treatment in older adults recommended in the currently
used guidelines. A secondary aim was to explore the poten-
tial relationships between the advised targets and guideline
characteristics, including methodological quality, continent
of origin, intended users and the guideline committee’s
selection of evidence supporting the recommended targets.
Methods
This systematic review is reported using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) recommendations [22]. The protocol was
registered in PROSPERO (CRD42020131021).
Data sources and searches
In consultation with a medical information specialist, we
designed a systematic search in PubMed, Emcare and
Embase for references published from 1 January 2008
(search date 15 July 2020). We combined search terms to
define ‘hypertension’, ‘high blood pressure’, ‘cardiovascular
diseases’ and the concept ‘guideline’. (Appendix 1, available
in Age and Ageing online, provides the complete strategies).
The search was limited to English language. In addition,
we searched the following websites and guideline-specific
databases: Clinical Practice Guidelines Infobase (CPG
Infobase; https://joulecma.ca/cpg/homepage); Guidelines
International Network (G-I-N; http://www.g-i-n.net);
National Guideline Clearinghouse (NGC; http://www.gui
deline.gov); Scottish Intercollegiate Guidelines Network
(SIGN; http://www.sign.ac.uk); and UpToDate (https://
www.uptodate.com/contents/search). For the database
extraction, we used corresponding search terms on 15 July
2020, except for NGC (access date 20 June 2018) due to
closure (16 July 2018) of the database.
Guideline selection
After removal of duplicate records, one investigator (JMKB)
screened the unique publications by title and abstract. Only
clinical practice guidelines were included, as defined by (i)
having been extracted from one of the guideline-specific
databases (see section Data Sources and Searches); (ii) being
recorded in Pubmed, Embase or Emcare AND describ-
ing itself as ‘guideline’ in the document title. Publications
that explicitly mentioned a disease-specific target population
and/or when full version was unavailable in English or inac-
cessible online, were not included in the full-text screening.
Summary reports or superseded documents were also not
included.
Two investigators (JMKB and LMvB) screened the full
text for the in- and exclusion criteria. For inclusion, guide-
lines had to (i) concern hypertension management in the
general adult population (no age limit) and (ii) include a
numerical threshold for initiation and/or target of antihy-
pertensive drug treatment. Exclusion criteria were: (i) exclu-
sively concerning secondary prevention; (ii) only disease-
specific hypertension management (e.g. diabetes mellitus or
kidney failure); (iii) full version unavailable in English or
inaccessible online; (iv) document explicitly describing itself
as a non-guideline; or (v) withdrawn. When a guideline
was published more than 5 years before another included
guideline from the same Society, it was considered super-
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meetings, led by a third author (RKEP) until consensus was
reached.
Data extraction
As defined by the inclusion criteria, all selected guidelines
contained a numerical threshold for initiation and/or target
of antihypertensive drug treatment in the general adult pop-
ulation. Specific advices concerning antihypertensive drug
therapy in context of age, ageing or frailty were extracted
from the included guidelines.
Two investigators (JMKB and LMvB) extracted in
context of primary cardiovascular prevention: (i) all age-
and frailty-related numerical advices (in mmHg) concerning
when to start antihypertensive drug therapy (=threshold) and
(ii) all age- and frailty-related numerical targets (in mmHg)
of antihypertensive drug treatment. To contextualize these
numbers, the corresponding thresholds for initiation and
targets in the general adult population (as defined by




Two investigators (JMKB and LMvB) individually assessed
the methodological quality of each guideline included in
the analysis using the Appraisal of Guidelines for Research
& Evaluation (AGREE) II online instrument [23]. The
AGREE II tool involves 23 items to be rated on a scale of 1
(strongly disagree) to 7 (strongly agree) corresponding to the
extent to which the criteria articulated in the User’s Manual
are met. These 23 items are grouped into six domains: (i)
scope and purpose, (ii) stakeholder involvement, (iii) rigor
of development, (iv) clarity of presentation, (v) applicability
and (vi) editorial independence. After independent appraisal
of all included guidelines, JMKB and LMvB discussed each
item with a difference of ≥3 points, adjusting the initial
rating if deemed appropriate. The final score for each domain
was calculated by summing the scores of both appraisers and
converting them to a percentage of the maximum domain
score for two appraisers. Additionally, an overall score was
acquired by calculating a weighted mean of the individual
domain scores (see Appendix 2, available in Age and Ageing
online, for details). We rated the quality of a guideline as
moderate-to-high when the weighted mean domain score
was fifty percent or more.
Continent of origin and intended users
For all guidelines, the origins were categorized in four conti-
nents: (i) Asia, (ii) Europe, (iii) North America and (iv) other
(including Africa, South America and Australia/Oceania).
Intended users were, as stated in the guideline, categorized
into three categories: (i) primary care, (ii) all health care
professionals and (iii) not explicitly mentioned.
Supporting evidence
Two investigators (JMKB and LMvB) individually assessed
the evidence supporting the advised targets. The complete
guideline, appendices and references to inform the recom-
mended values were checked. The supporting evidence was
then categorized into four categories: (i) only RCT evidence,
(ii) evidence from RCT’s and observational studies, (iii) pre-
dominantly based on other guidelines and (iv) no statement
concerning evidence used to underpin the recommended
targets and no direct link between references and targets.
Results
A total of 10,080 records were identified by a combined
search in PubMed, Embase and Emcare. After exclusion of
3,523 duplicates, 6,557 records were screened by title and
abstract, of which 177 were potentially relevant. An addi-
tional 43 records were identified through the screening of five
different databases (SIGN, NGC, GIN, CPG Infobase and
UpToDate). Full-text screening of these 220 records yielded
42 unique guidelines that contained a numerical threshold
for initiation and/or target of non-disease-specific antihyper-
tensive drug treatment in context of primary prevention. The
reasons of exclusion of the other 178 records are described in
Figure 1 (PRISMA flow chart) [22].
Thirty-four (81%), of the total of 42 primary prevention
guidelines with a numerical value concerning antihyper-
tensive drug therapy provided recommendations regarding
hypertension management in context of age, ageing or frailty
and were included in the current analysis.
The 34 included guidelines originated from six different
continents (Africa, Asia, Australia, Europe, North America,
and South America). Table 1 summarizes the main charac-
teristics of the included guidelines.
Initiation of antihypertensive drug treatments
Thirty-two of 34 included guidelines (excluding [35, 42])
recommended both at least one explicit BP threshold
for the start of antihypertensive drug treatment and a
corresponding target. A detailed overview of all values is
displayed in Table 1. Twenty-three (68%) guidelines-based
threshold values on age and/or frailty status, or explicitly
mentioned to start drug treatment in older adults according
to the same principles as in the general population. The
subgroups of chronological age used to describe treatment
recommendations were: ≥60–65 years (n = 7), both ≥60–
65 and ≥80 years (n = 7), ≥80 years (n = 4) and ≥ 75 years
(n = 2). The three remaining guidelines used the terms
‘elderly’ and ‘older patients’ [28, 34, 40].
While 4 out of 23 (17%) guidelines advised lower thresh-
olds for older adults, four guidelines recommended higher
thresholds for initiation of antihypertensive drug treatment.
Eleven advised comparable values for middle-aged and older
adults, of which a majority described separate thresholds for
initiation of lifestyle management (LSM) and drug therapy
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Figure 1. PRISMA flow chart of guideline selection process.
on hypertension management in older adults. The distribu-
tion of the recommended threshold values in older adults
in comparison with the general population is displayed in
Table 2.
Although frequently mentioned, only three of all 34
(9%) guidelines recommended a threshold specifically for
the initiation of antihypertensive drug therapy in older
adults with frailty. All three guidelines advised the start of
pharmacological treatment when systolic blood pressure
(SBP) is equal to or higher than 160 mmHg. Whereas one
guideline did not define the term frailty [49], the other
two guidelines included multiple frailty assessment tools
[28, 47].
Targets of antihypertensive drug treatment
All thirty-four included guidelines recommended at least
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Table 2. Distribution of the thresholds for initiation and targets of antihypertensive drug treatment in older adults
recommended in the 34 included guidelines for primary prevention of cardiovascular diseases. The numbers in the table
correspond with the individual reference (ref.) of the guideline
Value in comparison to the general
population
Lower Higher Comparable Only older adults No value or not specific
for older adults
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Threshold (ref.) 24, 31, 41, 54 26, 40, 50, 51 29, 32, 33, 34, 36,
43, 44, 45, 49, 52, 53
28, 38, 46, 47 25, 27, 30, 35, 37, 39,
42, 48, 55, 56, 57
Target (ref.) 65–70 years 48 26, 33, 36, 44, 45,
50, 52, 55, 56, 57
24, 25, 27, 29, 30,
31, 32, 35, 37, 40,
41, 42, 43, 49, 51,
53, 54
28, 38, 46, 47 34, 39
≥80 years 30, 48, 54 25, 26, 27, 29, 32,
33, 36, 37, 40, 42,
43, 44, 45, 50, 51,
52, 53, 55, 56, 57
24, 31, 35, 41, 49 28, 38, 46, 47 34, 39
treatment. A detailed overview of all target values is dis-
played in Table 1. Thirty-two guidelines (excluding [34, 39])
described specific BP targets for older adults in context of
age and/or frailty. Thirty-one (excluding [28, 34, 39]) used
chronological age as one of the factors in advising targets.
The subgroups of chronological age for description of targets
were: both ≥60–65 and ≥80 years (n = 10), ≥60–65 years
(n = 9), ≥80 years (n = 6), ≥75 years (n = 5) and both ≥60
and ≥70 years (n = 1).
Twenty-eight guidelines (excluding [28, 34, 38, 39, 46,
47]) gave both explicit targets for the general adult popula-
tion and older adults. For adults 65–70 years, 17 guidelines
recommended the same target in comparison with the gen-
eral population, while 10 advised a higher target. Only one
recently updated guideline endorsed a lower SBP value for
this group of older adults in comparison to the target in the
general population [48]. Twenty guidelines advised a higher
target for the oldest old compared to the general population.
In contrast, three guidelines recommended a lower target.
Five guidelines endorsed the same target of antihypertensive
drug therapy for the oldest old as for the general population.
The distribution of the recommended targets in older adults
in comparison with the general population is displayed in
Table 2.
Over half of the guidelines (n = 18) recommended explic-
itly or implicitly to treat hypertension in adults aged 80 years
and older to a target lower than 150 mmHg. The other
15 guidelines advised more intensive treatment targets for
the oldest old. Targets of SBP lower than 130 or even
120 mmHg were endorsed by four different guidelines [30,
41, 48, 54].
Many guidelines gave non-numerical recommendations
concerning intensity of treatment in frail older adults, such
as ‘ . . . if tolerated but consider an individualised BP target
in context of frailty, independence and likely tolerability of
treatment.’ [56]. However, only two of all 34 (6%) guidelines
included in the analysis advised an unambiguous target. One
guideline recommended to lower SBP in frail older adults
<150 mmHg [47], while the other advised to target a SBP
<160 mmHg in the frail and <190 mmHg in the very frail
[28].
Recommended targets and guideline
characteristics
Quality assessment
The quality appraisal by AGREE domain scores for each
individual guideline is provided in Appendix 3, available
in Age and Ageing online. The domains ‘Scope and Purpose’
and ‘Clarity of Presentation’ were assigned the highest overall
median scores of 68% (range 28–100%) and 86% (range
42–97%) respectively. The domain ‘Editorial Independence’
was assigned the lowest median score of 33% (range 0–
100%). The domains ‘Rigor of Development’ and ‘Applicabil-
ity’ , both scoring 34%, were as well generally underreported.
Five guidelines scored ≥50% on all six domains and were
overall of very good quality. The weighted mean domain
score of an additional nine guidelines was ≥50%. Those
14 guidelines together were labelled as of moderate-to-high
quality. An overview of the advised target values of antihy-
pertensive drug therapy in context of chronological age in
these 14 guidelines is summarized in Figure 2a. The advised
targets of the other 20 guidelines are displayed in Figure 2b.
While approximately more than 60% of the guidelines in
Figure 2b suggest to target <140 and <150 mmHg in older
adults respectively below and above the age of 80 years, the
guidelines of moderate-to-high quality are less consistent.
In this subset of rigorously developed guidelines, targets of
<150 mmHg (43%), <140 mmHg (36%), <130 mmHg
(7%), and, <120 mmHg (14%) were advised in the old-
est old.
Continent of origin and intended users
An overview of the advised target values of SBP according
to the continent of origin of the corresponding guideline is
summarized in Figure 3(1). When grouped per continent of
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Figure 2. (a). Targets of systolic blood pressure according to age group (in years) recommended in the 14 guidelines of moderate-
to-high quality. (b). Targets of systolic blood pressure according to age group (in years) recommended in the 20 other included
guidelines.
for adults above the age of 80 years, most predominant in
North American guidelines. The same variation was seen
when categorized by intended users (Figure 3(2)).
Supporting evidence
Almost all guidelines described or referred to the evidence
that was used to support the advised targets (Figure 3(3)).
Guidelines that limited supporting evidence to RCT’s rec-
ommended a target <140 mmHg in adults below the age
of 75 years. But otherwise, a variation was seen among all
categories, especially for the oldest old.
Discussion
In this systematic review of currently used guidelines on
primary cardiovascular prevention, we searched for initiation
thresholds and targets of antihypertensive drug treatment in
older adults. Thirty-four of the 42 (81%) eligible guidelines
did include explicit recommendations regarding antihyper-
tensive drug therapy in old age. Most guidelines gave either
no specific threshold for drug therapy in the older patient
or one comparable to the general population. Correspond-
ing targets of treatment, notably for the oldest old, were
especially across the most rigorously developed guidelines
less consistent. This variation between guidelines with the
highest quality was also seen when categorized into conti-
nent of origin, intended users and supporting evidence. For
octogenarians, targets of SBP varied largely from <120 to
<150 mmHg. Guidelines do consider biological aspects of
ageing, but only a very small minority recommends specific
threshold and target values for antihypertensive drug therapy
in the frail older patient.
In an earlier systematic review of guidelines on hyperten-
sion in older adults (search date December 2014), Alhawassi
et al . [58] describe a consistency across all guidelines
concerning titration of drug therapy to a SBP target of 140–
150 mmHg. But despite this consistency, the authors note
a continuous scientific debate among experts regarding the
optimal target in older adults and the at that time lacking
robust trial evidence. A half-decade later, we observe targets
ranging from <150 to <120 mmHg (see Figure 2a and b)
for the oldest old, reflecting that this debate among experts
has been introduced into clinical guidelines. The Systolic
Blood Pressure Intervention Trial (SPRINT) [19, 59] is a
landmark RCT that plays a pivotal role in this ongoing
discussion regarding the optimal target of antihypertensive
drug therapy in older adults. SPRINT supports that a target
of SBP <120 mmHg in non-diabetic adults above the age
of 65 years safely reduces cardiovascular risk. However,
the results of SPRINT are not yet unanimously endorsed
in the currently used guidelines. This is in contrast to
the Hypertension in the Very Elderly Trial (HYVET)
[60], an other RCT that showed the benefits of treating
hypertensive (SBP >160 mmHg) octogenarians to the
nowadays in guidelines more widely implemented target
of <150 mmHg (see Figure 2a and b). Although the results
of SPRINT [19] became available 7 years after those of
HYVET [60], 82% of the included guidelines in this review
were published after SPRINT. The European experts of the
2018 ESC/ESH guideline embrace SPRINT, but translate
the closely monitored RCT setting to a real-life target of
130–139 mmHg in adults 65 years and older [44]. Both
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Figure 3. Targets of systolic blood pressure according to age group (in years) recommended in all 34 guidelines according to
continent of origin (1), intended users (2) and supporting evidence of the recommended targets (3).
however, due to their exclusion criteria, the generalisability
of both trials to the heterogeneous population of older
adults remains a matter of debate [10, 12]. In adults
aged under 75, this target value is the scarce consistent
recommendation when we limit the included guidelines to
those with targets based on RCT’s. (see Figure 3a). Robust
older adults certainly benefit from a SBP <140 mmHg [7–9,
18], however, we found that only two guidelines in line with
observational studies suggest different SBP target values for
frail compared to vital older adults [28, 47]. Nonetheless, in
comparison with a systematic review published in 2015 by
Jansen et al . [61], guidelines increasingly denote frailty as a
factor to consider when setting thresholds for the start and
targets of antihypertensive drug therapy (see Table 1).
The current evidence gaps concerning targets of antihy-
pertensive therapy for older adults, especially for the frail,
necessitates scientific committees to combine trial evidence
with observational data and consensus among experts for
guideline development. The significant share of expert
opinion in those guidance documents appears to result in
a variety of recommended targets. We support the growing
consensus that a large RCT is needed to provide sufficient
evidence for the (de) prescribing and optimal intensity of
antihypertensive drug therapy in the frail older population
[12, 20, 62, 63]. Although this study design carries with it
well-known difficulties such as feasibility and strict
inclusion and exclusion criteria, it could come up with
additional insights into the net benefit of antihypertensive
drug treatment in frail older adults.
Strengths and limitations
To our knowledge, this is the first study that systematically
screened the currently used guidelines for thresholds and
targets of antihypertensive drug therapy specifically for older
adults with frailty. The other strengths of this study include a
systematic search that resulted in a comprehensive overview
of the threshold and target values of antihypertensive drug
therapy recommended in the currently used international
hypertension guidelines. Moreover, the extensiveness of our
search resulted in an overview of guidelines not only orig-
inating from high income countries. Furthermore, the use
of a validated tool [23] that appraises the methodology of
a guideline allowed us to present the endorsed targets of
treatment in light of the overall quality of the corresponding
document.
A limitation of this study is that we only included guide-
lines in English language. At least two non–English-language
guidelines (in Norwegian [64] and Dutch [65]) advise targets
for antihypertensive treatment in older adults, but were
not included in this study. Nonetheless, our review pro-
vides an overview of thresholds and targets from guidelines
originating from all over the world. A second limitation may
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the currently used guidelines; however, 16 (47%) of the total
of 34 included guidelines were published in the last three
years. Furthermore, 7 (50%) of the moderate-to-high quality
guidelines were issued in 2018 or later. A third limitation is
that only one author performed the first screening by title
and abstract. However, since this straightforward step was
conducted in eight distinct databases, it is unlikely that many
important guidelines were missed. Finally, we restricted the
extraction of targets and thresholds to the context of age,
ageing and frailty. Thresholds and targets in context of frailty
related terms such as ‘limited life expectancy’, ‘multimorbid-
ity’ and ‘nursing home’ were not systemically extracted, since
this would change the scope of the review.
Conclusion
The subject of antihypertensive drug treatment in older
adults is well addressed in current international guidelines for
primary prevention of cardiovascular diseases. The ongoing
scientific and clinical debate concerning how low the target
of treatment needs to be, however, is reflected in an incon-
sistency of recommendations across guidelines especially for
adults aged 80 years and older. This inconsistency is inde-
pendent of methodological quality, originating continent,
intended users and supporting evidence of the guideline.
Clinical practice guidelines are developed to standardize
treatment, but currently challenge physicians to exercise
very active reading and clinical judgement in a complex
medical context, especially when treating a frail older adult.
In order to accommodate clinical judgement in geriatric
cardiovascular prevention, it would be helpful if guidelines
defined targets more on base of biological aspects of ageing
such as frailty rather than merely on base of chronological
age alone. Research that incorporates this heterogeneity in
older persons will possibly lead to more uniform guidelines
on hypertension management in old age.
Supplementary Data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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